FDA staffers and outside experts worry the program runs afoul of legal, ethical and scientific standards used to review new ...
More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback